Glaukos Corp Stock
Glaukos Corp Stock
The price for the Glaukos Corp stock decreased slightly today. Compared to yesterday there is a change of €0.000 (-0.540%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Glaukos Corp stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Glaukos Corp in the next few years
Pros
?
S********** s********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Glaukos Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Glaukos Corp | -0.540% | -0.543% | 26.207% | -31.203% | -35.106% | 111.806% | 56.410% |
| Icu Medical Inc. | 0.000% | -4.724% | -0.820% | -17.687% | -17.687% | -16.552% | -26.220% |
| Bio-Rad Labs Inc. A | -2.130% | -4.419% | 4.053% | -14.689% | -12.544% | -28.464% | -40.797% |
| Neogen Corp. | 0.980% | -0.962% | -0.962% | -59.127% | -57.083% | - | - |
News
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.
Brown Capital
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by
Glaukos (GKOS) Q2 Revenue Jumps 30%
Glaukos (NYSE:GKOS), a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of